ABO 401
Alternative Names: ABO-401; AIM™ AAV204 CFTR; AIM™ AAV204.CFTRLatest Information Update: 28 Jul 2022
At a glance
- Originator Abeona Therapeutics
- Class Gene therapies
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cystic fibrosis
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Cystic-fibrosis in USA (Parenteral)
- 20 Jan 2020 University of North Carolina’s (UNC) has patent protection for adeno-associated virus (AAV) vectors targeted for central nervous system
- 20 Jan 2020 University of North Carolina’s (UNC) has patents pending for Abeona's AAV204 based gene therapy vector compositions .